Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

BACKGROUND: To determine the dose-limiting toxicity (DLT), maximum tolerated dose, recommended dose (RD) and preliminary evidence of activity of escalating doses of irinotecan (CPT-11) fixed-dose-rate infusional gemcitabine (FDR-GMB) and bevacizumab in pretreated metastatic colorectal cancer (mCRC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Abajo, A, Rodriguez, J, Bitarte, N, Zarate, R, Boni, V, Ponz, M, Chopitea, A, Bandres, E, Garcia-Foncillas, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990573/
https://www.ncbi.nlm.nih.gov/pubmed/20940716
http://dx.doi.org/10.1038/sj.bjc.6605908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990573/
https://www.ncbi.nlm.nih.gov/pubmed/20940716
http://dx.doi.org/10.1038/sj.bjc.6605908

Ejemplares similares